Login
Immunocore Holdings plc logo

Immunocore Holdings plc

immunocore.com

What Do They Do?

Sells KIMMTRAK, a therapy for people with uveal melanoma, and develops immune-targeting medicines for cancer, infectious diseases and autoimmune diseases.

How Do They Make Money?

Distributors are invoiced for KIMMTRAK; sales are counted when it is delivered or when distributors take it from consignment inventory. Historical collaboration agreements brought upfront and milestone payments for technology rights, with related research work carried out over time.

FY2025 revenue by product or service revenue
SegmentShareRevenue
Revenue from sale of therapies, net
Sold outright

100%
FY2022: 81%
Collaboration revenue
0.0%
FY2022: 19%

Who Are Their Customers?

Distributors are the main customers in the United States and Europe; in some countries, hospitals and healthcare providers buy through agents. Medison and Er-Kim distribute KIMMTRAK in certain markets outside the United States.

Customers above 10% of revenue, FY2025
of revenue from four customers (23%, 23%, 17%, 18%)
FY2023: 88% from four customers

Do Revenues Turn Into Profits?

No. It lost $35.5M in FY2025.

Operating income, FY2025
−11% of revenue
▲ +36% (Loss) vs FY2024 (−$70.5M, −23%)
Net income, FY2025
−9% of revenue
▲ +30% (Loss) vs FY2024 (−$51.1M, −16%)
Free cash flow, FY2025
−4% of revenue
▼ Turned to a loss vs FY2024 ($20.9M, 7%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▼ −1%
vs $103.7M in Q3 FY2025
Net income
▼ −7935% (Loss)
vs −$177K in Q3 FY2025
Revenue from sale of therapies, net share of revenue vs 100.0% in Q3 FY2025

Added regional distributor The company added Er-Kim alongside Medison to distribute and commercialize KIMMTRAK in Turkey, the Middle East, North Africa, the Caucasus and the Commonwealth of Independent States.

Revenue over time
Revenue from sale of therapies, net Collaboration revenue
$500M$250M$0

Who Do They Compete With?

Competes with Adaptimmune Therapeutics, Immatics Biotechnologies, Adaptive Biotechnologies, pure MHC, BioNTech, Genentech, Enara Bio, Boehringer Ingelheim International, Anocca, T-Knife, 3T Biosciences, Regeneron Pharmaceuticals, Takara Bio, AstraZeneca, Lion TCR, TCRCure Biopharma, Corregene Biotechnology, TScan Therapeutics, Molecular Partners, and Crossbow Therapeutics

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support